RxDoctor Payments Data

Manish Champaneria, MD

Plastic and Reconstructive Surgery · San Diego, CANPI 1437356375

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (39.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Kerecis Limited accounts for 78.0% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $7,096 and has fallen 90.4% since, to $681 in 2025.

$15,654in general payments, 2019–2025

Across 82 payments — averaging $190.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$12K
  • AbbVie$1K
  • Mentor Worldwide LLC$823
  • Innovation Technologies Inc$254
  • Sientra, Inc.$201
  • TELA Bio, Inc.$161
  • plus $999 from 14 others

What the payments were for

  • Consulting fees$6,22540%
  • Speaking & faculty fees$5,10033%
  • Travel & lodging$3822%
  • Food & beverage$3,94825%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,654 in reported general payments places this provider in the 85th percentile of 349 plastic and reconstructive surgery providers in California.

See all plastic and reconstructive surgery providers in California

Medicare billing

Part B allowed, 2024
$73,713
Medicare patients
75
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen14$196
Cephalexin13$68

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →